Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer

a phase I study.

D. I. Rosenthal, O. Okani, J. Corak, D. Kavanaugh, B. Kamen, F. M. Vuitch, A. F. Gazdar, J. Greiner, E. F. Frenkel, D. P. Carbone

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation therapy (RT) for previously untreated, locally advanced non-small cell lung cancers. Eligible patients have locally advanced (T4NXM0 or TXN2-3M0) non-small cell cancer ineligible for potentially curative surgical resection, a good performance status, adequate hematologic, hepatic, and renal functions, and no distant metastases. All patients receive a total tumor dose of 64.8 Gy megavoltage RT in 7 weeks at 1.8 Gy once daily, 5 d/wk. Paclitaxel is delivered by continuous intravenous infusion starting 48 hours before RT and continuing for its duration. The dose of paclitaxel is escalated in cohorts of three patients in a standard phase I design. To date, 16 patients have entered the trial, and 15 are evaluable for toxicity in this ongoing study. Paclitaxel dose is currently at a 6.5 mg/m2/d dose level, with no dose-limiting toxicity recorded thus far. One patient at the highest dose level has had grade 2 pneumonitis. With the exception of anemia, toxicities are those that would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. These findings indicate that this therapy is feasible and well tolerated through current dose levels, with no dose-limiting toxicity. Dose escalation is ongoing.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number4 Suppl 12
StatePublished - Aug 1997

Fingerprint

Paclitaxel
Non-Small Cell Lung Carcinoma
Radiotherapy
Anemia
Kidney
Radiation Dosage
National Cancer Institute (U.S.)
Intravenous Infusions
Neoplasms
Pneumonia
Pharmacokinetics
Neoplasm Metastasis
Liver
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Rosenthal, D. I., Okani, O., Corak, J., Kavanaugh, D., Kamen, B., Vuitch, F. M., ... Carbone, D. P. (1997). Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. Seminars in Oncology, 24(4 Suppl 12).

Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer : a phase I study. / Rosenthal, D. I.; Okani, O.; Corak, J.; Kavanaugh, D.; Kamen, B.; Vuitch, F. M.; Gazdar, A. F.; Greiner, J.; Frenkel, E. F.; Carbone, D. P.

In: Seminars in Oncology, Vol. 24, No. 4 Suppl 12, 08.1997.

Research output: Contribution to journalArticle

Rosenthal, DI, Okani, O, Corak, J, Kavanaugh, D, Kamen, B, Vuitch, FM, Gazdar, AF, Greiner, J, Frenkel, EF & Carbone, DP 1997, 'Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.', Seminars in Oncology, vol. 24, no. 4 Suppl 12.
Rosenthal, D. I. ; Okani, O. ; Corak, J. ; Kavanaugh, D. ; Kamen, B. ; Vuitch, F. M. ; Gazdar, A. F. ; Greiner, J. ; Frenkel, E. F. ; Carbone, D. P. / Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer : a phase I study. In: Seminars in Oncology. 1997 ; Vol. 24, No. 4 Suppl 12.
@article{b18c9d4d25274a049e9611883e74789b,
title = "Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.",
abstract = "The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation therapy (RT) for previously untreated, locally advanced non-small cell lung cancers. Eligible patients have locally advanced (T4NXM0 or TXN2-3M0) non-small cell cancer ineligible for potentially curative surgical resection, a good performance status, adequate hematologic, hepatic, and renal functions, and no distant metastases. All patients receive a total tumor dose of 64.8 Gy megavoltage RT in 7 weeks at 1.8 Gy once daily, 5 d/wk. Paclitaxel is delivered by continuous intravenous infusion starting 48 hours before RT and continuing for its duration. The dose of paclitaxel is escalated in cohorts of three patients in a standard phase I design. To date, 16 patients have entered the trial, and 15 are evaluable for toxicity in this ongoing study. Paclitaxel dose is currently at a 6.5 mg/m2/d dose level, with no dose-limiting toxicity recorded thus far. One patient at the highest dose level has had grade 2 pneumonitis. With the exception of anemia, toxicities are those that would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. These findings indicate that this therapy is feasible and well tolerated through current dose levels, with no dose-limiting toxicity. Dose escalation is ongoing.",
author = "Rosenthal, {D. I.} and O. Okani and J. Corak and D. Kavanaugh and B. Kamen and Vuitch, {F. M.} and Gazdar, {A. F.} and J. Greiner and Frenkel, {E. F.} and Carbone, {D. P.}",
year = "1997",
month = "8",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 Suppl 12",

}

TY - JOUR

T1 - Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer

T2 - a phase I study.

AU - Rosenthal, D. I.

AU - Okani, O.

AU - Corak, J.

AU - Kavanaugh, D.

AU - Kamen, B.

AU - Vuitch, F. M.

AU - Gazdar, A. F.

AU - Greiner, J.

AU - Frenkel, E. F.

AU - Carbone, D. P.

PY - 1997/8

Y1 - 1997/8

N2 - The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation therapy (RT) for previously untreated, locally advanced non-small cell lung cancers. Eligible patients have locally advanced (T4NXM0 or TXN2-3M0) non-small cell cancer ineligible for potentially curative surgical resection, a good performance status, adequate hematologic, hepatic, and renal functions, and no distant metastases. All patients receive a total tumor dose of 64.8 Gy megavoltage RT in 7 weeks at 1.8 Gy once daily, 5 d/wk. Paclitaxel is delivered by continuous intravenous infusion starting 48 hours before RT and continuing for its duration. The dose of paclitaxel is escalated in cohorts of three patients in a standard phase I design. To date, 16 patients have entered the trial, and 15 are evaluable for toxicity in this ongoing study. Paclitaxel dose is currently at a 6.5 mg/m2/d dose level, with no dose-limiting toxicity recorded thus far. One patient at the highest dose level has had grade 2 pneumonitis. With the exception of anemia, toxicities are those that would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. These findings indicate that this therapy is feasible and well tolerated through current dose levels, with no dose-limiting toxicity. Dose escalation is ongoing.

AB - The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation therapy (RT) for previously untreated, locally advanced non-small cell lung cancers. Eligible patients have locally advanced (T4NXM0 or TXN2-3M0) non-small cell cancer ineligible for potentially curative surgical resection, a good performance status, adequate hematologic, hepatic, and renal functions, and no distant metastases. All patients receive a total tumor dose of 64.8 Gy megavoltage RT in 7 weeks at 1.8 Gy once daily, 5 d/wk. Paclitaxel is delivered by continuous intravenous infusion starting 48 hours before RT and continuing for its duration. The dose of paclitaxel is escalated in cohorts of three patients in a standard phase I design. To date, 16 patients have entered the trial, and 15 are evaluable for toxicity in this ongoing study. Paclitaxel dose is currently at a 6.5 mg/m2/d dose level, with no dose-limiting toxicity recorded thus far. One patient at the highest dose level has had grade 2 pneumonitis. With the exception of anemia, toxicities are those that would be expected from RT alone. A slowly progressive normocytic anemia with no renal dysfunction was found to be associated with an acquired hypoerythropoietin state. These findings indicate that this therapy is feasible and well tolerated through current dose levels, with no dose-limiting toxicity. Dose escalation is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=0031201598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031201598&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 Suppl 12

ER -